Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iSCLife X-Young is an anti-aging stem cell therapy developed by Sclnow Biotechnology. The therapy utilizes umbilical cord-derived mesenchymal stem cells (UC-MSCs) that are administered systemically to promote the renewal and activity of cells throughout the body. These stem cells function through self-replication and multi-directional differentiation, as well as the secretion of regulatory paracrine factors. These factors help inhibit apoptosis in damaged tissues, reduce inflammation, and improve micro-circulation, collectively working to repair senile cells and delay the physiological effects of aging. The therapy is designed to target cellular senescence and aging-related changes through systemic regeneration and paracrine signaling mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iSCLife X-Young.